These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20629520)

  • 41. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
    Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
    Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dasatinib.
    Lindauer M; Hochhaus A
    Recent Results Cancer Res; 2014; 201():27-65. PubMed ID: 24756784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.
    Pitini V; Arrigo C; Di Mirto C; Mondello P; Altavilla G
    Lung Cancer; 2013 Oct; 82(1):171-2. PubMed ID: 23932362
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful pregnancy occurring with interferon-alpha therapy in chronic myeloid leukemia.
    Mesquita MM; Pestana A; Mota A
    Acta Obstet Gynecol Scand; 2005 Mar; 84(3):300-1. PubMed ID: 15715542
    [No Abstract]   [Full Text] [Related]  

  • 45. Fatherhood during imatinib.
    Shash E; Bassi S; Cocorocchio E; Colpi GM; Cinieri S; Peccatori FA
    Acta Oncol; 2011 Jun; 50(5):734-5. PubMed ID: 21517714
    [No Abstract]   [Full Text] [Related]  

  • 46. Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
    Faber E; Mojzikova R; Plachy R; Rozmanova S; Stastny M; Divoka M; Jarosova M; Indrak K; Divoky V
    Leuk Res; 2010 Apr; 34(4):e91-3. PubMed ID: 19811824
    [No Abstract]   [Full Text] [Related]  

  • 47. Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment.
    Chang H; Hung YS; Chou WC
    Int J Infect Dis; 2014 Aug; 25():165-7. PubMed ID: 24932855
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients?
    Eskazan AE; Soysal T; Erbilgin Y; Ozbek U; Ferhanoglu B
    Leuk Res; 2011 Sep; 35(9):e145-6. PubMed ID: 21605905
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
    Taylor MJ; Scuffham PA
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
    Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
    J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
    [No Abstract]   [Full Text] [Related]  

  • 51. Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report.
    Buyukbayrak EE; Ergen B; Karsidag YK; Kars B; Turan C; Argon D
    Arch Gynecol Obstet; 2008 Aug; 278(2):161-3. PubMed ID: 18193246
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy.
    Abdelhalim A; Barcos M; Block AW; Sait SN; Starostik P; Wetzler M; Wang ES
    Leuk Lymphoma; 2007 May; 48(5):1053-6. PubMed ID: 17487757
    [No Abstract]   [Full Text] [Related]  

  • 53. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dasatinib.
    Shah NP
    Drugs Today (Barc); 2007 Jan; 43(1):5-12. PubMed ID: 17315048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia.
    Grisouard J; Ojeda-Uribe M; Looser R; Hao-Shen H; Lundberg P; Duek A; Jeandidier E; Karow A; Skoda RC
    Blood; 2013 Nov; 122(22):3694-6. PubMed ID: 24263960
    [No Abstract]   [Full Text] [Related]  

  • 57. Basophilic blast phase of chronic myelogenous leukemia.
    Babiker HM; Proytcheva M
    Blood; 2014 Oct; 124(15):2464. PubMed ID: 25436261
    [No Abstract]   [Full Text] [Related]  

  • 58. Impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia.
    Santos FM; Ghelfond G; Seguro FS; Abdo ANR; Dalessandro T; Maciel FVR; Bassolli L; Rocha V; Bendit I
    Am J Hematol; 2022 Feb; 97(2):E72-E74. PubMed ID: 34822180
    [No Abstract]   [Full Text] [Related]  

  • 59. Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report.
    Baykal C; Zengin N; Coşkun F; Güler N; Ayhan A
    Eur J Gynaecol Oncol; 2000; 21(1):89-90. PubMed ID: 10726630
    [No Abstract]   [Full Text] [Related]  

  • 60. Successful pregnancy and delivery during alpha-interferon therapy for chronic myeloid leukemia.
    Crump M; Wang XH; Sermer M; Keating A
    Am J Hematol; 1992 Jul; 40(3):238-9. PubMed ID: 1609781
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.